From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Government Building ‘Fill and Finish’ Network for Pandemic Influenza Vaccines

by Global Biodefense Staff
April 1, 2013

Biodefense Vaccine ProgramThe United States Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) is looking to establish a Fill and Finish Manufacturing Network (FFMN) in the U.S. that facilitates medical countermeasure surge requirements during biodefense emergencies. 

These facilities are expected to provide filling and finishing capabilities for influenza vaccines and possibly for pharmaceuticals against CBRN threats or to support fill finishing for other drug shortages.

The effort is intended to create the necessary contractual, business and regulatory relationships with organizations that hold the license for pandemic influenza products to meet the stated HHS objective of having 600 million doses of pandemic influenza vaccine available in 6 months, in response to any pandemic.

It is anticipated that the majority of the time leading up to the fill and finish of 600 million doses will be occupied by viral seed selection and preparation, vaccine bulk drug substance manufacture, reagent development and bulk product release.

At this point, the FFMN will respond in parallel to the filling of pandemic influenza vaccine in finished multi-dose vials with complete internal testing, at the government’s direction. 

During non-pandemic periods, a warm-base effort may be executed with Fill and Finish Network members to ensure their capabilities are maintained in a state of readiness.

Initial work under the FFMN contract will be for technology modifications, if necessary, of existing equipment within pharmaceutical fill and finish facilities to meet FDA and cGMP standards for clinical, and Phase 3 Clinical, Commercial-scale fill and finish needs of the government. This phase will also include support to the vaccine owner for submitting a license amendment for this new alternate fill/finish site.

Further details are available under Solicitation Number BARDA-13-100-SOL-00004. Companies have until April 9, 2013 to submit their proposals.

From Our Partners
Tags: ASPRBARDAHHSInfluenzaPandemicRequest for ProposalsVaccines

Related Posts

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps
Outbreak News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies
Biosurveillance

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC